Education / Research

What the Research Says About Psilocybin

Last reviewed

For the first time in decades, universities are taking a careful look at psilocybin, the main active compound in sacred mushrooms. Johns Hopkins, Yale, and research groups around the world are running real trials, and some of the early results are striking.

This page walks through what has been found, how strong each finding is, and the questions nobody has answered yet. Every study links to its source, so you can read it yourself.

A note on names: many people call these mushrooms magic mushrooms, and we usually say sacred mushrooms. Researchers write about the compound itself, psilocybin, so this page does too.

How we label the evidence

Randomized trials
People were assigned by chance to psilocybin or a comparison, which is the strongest design for testing an effect.
Small or open-label trials
Real clinical studies, but small, or without a blinded comparison group. Good for spotting leads, not for settling them.
Case reports and surveys
Individual patients or self-reported answers. These raise questions; they cannot answer them.
Trials underway
Registered studies that are still running. We could not find published results.

Psilocybin and depression

This is the best-studied area, and the one where the results are strongest so far.

Randomized trials

Fifteen trials, one clear direction

A living review, which updates as new trials arrive, pooled 15 randomized trials with 801 people. On average, depression scores fell meaningfully more in the groups given psilocybin than in comparison groups. In the main analysis (12 trials, 585 people) the effect size was 0.90, which researchers usually call large.

Worth knowing

The authors flag that many of the included studies were small or at risk of bias. Because the experience is noticeable, people in these trials can often tell what they were given, which can inflate results.

Randomized trials

One session, still there six weeks later

In a randomized trial of 104 adults with major depression, one psilocybin session with psychological support was compared with an active placebo, a substance chosen so that people would feel something. Improvement showed up quickly and was still there at the six-week check. No serious treatment-related adverse events occurred. Headache, nausea, and visual effects were common on the day.

Worth knowing

Most people could tell which one they received. Follow-up was six weeks, and the group was mostly white and higher income.

Psilocybin and quitting smoking

A pilot study at Johns Hopkins compared psilocybin with the nicotine patch.

Randomized trials

A single session versus the patch

Eighty-two smokers were randomized to one supported psilocybin session or to the nicotine patch, and both groups received the same counseling program. Six months later, 40.5% of the first group had stayed quit, compared with 10% on the patch. No serious treatment-related adverse events occurred. Temporary rises in blood pressure, headache, and nausea were the expected effects.

Worth knowing

It was a pilot, and everyone knew which treatment they were getting. About two thirds had used psychedelics before, and the psilocybin group also had more time with staff.

Psilocybin and migraine or cluster headache

Headache research is early and small, but it is some of the more surprising work in the field.

Small or open-label trials

A small Yale study on migraine

Ten adults with migraine took part in a double-blind crossover study, where each person received both psilocybin and a placebo on separate occasions. In the two weeks after a single session, weekly migraine days dropped by about 1.65 after psilocybin and by about 0.15 after placebo.

Worth knowing

Ten people is a pilot. It is a reason to run a larger study, not a result to lean on.

Small or open-label trials

Cluster headache: promising, not settled

A small Yale trial first tested a three-dose course of psilocybin against placebo and saw about a 30 percent drop in cluster attacks that was not statistically significant. In a follow-up round, ten people all received psilocybin without knowing the dose, and weekly attacks fell from about 18 to about 10 over three weeks. How strong the experience was did not track with how much attacks dropped, though ten people is too few to be sure of that.

Worth knowing

The follow-up round had no placebo group and only ten people, none of them representative of everyone with cluster headache. The authors call for larger, longer studies.

Psilocybin and chronic pain

Here the honest summary is that the questions are ahead of the answers.

Case reports and surveys

Three patients, self-reported

A case series described three patients with nerve pain who used very low amounts of psilocybin and reported relief.

Worth knowing

There was no control group and the reports came from the patients themselves. Reviews rate the evidence as low or very low certainty.

Trials underway

Lower back pain

A registered trial is studying psilocybin for chronic lower back pain.

Worth knowing

No published results found.

ClinicalTrials.gov NCT05351541 →
Trials underway

Fibromyalgia, open-label

A registered open-label study is looking at fibromyalgia.

Worth knowing

No published results found.

ClinicalTrials.gov NCT05128162 →
Trials underway

Fibromyalgia, placebo-controlled

A registered placebo-controlled trial is testing two low amounts of psilocybin against placebo.

Worth knowing

No published results found.

ClinicalTrials.gov NCT06368492 →

Psilocybin microdosing: a question still being answered

Microdosing is where personal experience and lab results sit furthest apart, which makes it one of the most interesting questions in the field. Many people describe steadier mood, better focus, and more creativity. Surveys say much the same: in one analysis of 278 people's own accounts, improved mood and focus were the benefits mentioned most, though some also reported physical discomfort or more anxiety.

Researchers have started testing it with placebos. In a large study where 191 people ran their own blinded protocol, everyone improved over four weeks, whether they took the real thing or a placebo, so the study could not pull the two apart. In a lab study of 34 people, a small dose of dried mushrooms produced real, measurable effects, including changes in brain activity, but no clear shift in mood or creativity on the days tested. The effects were clearest in people who correctly guessed what they had taken, and a few thinking tests showed small changes in the other direction.

So the honest answer today is that nobody knows yet how much of what people report comes from the mushroom itself, how much from the intention and routine around it, and how much from the two working together. Those are not rivals. Expectation and routine are a real part of any practice. The studies so far were short and mostly in healthy volunteers, and longer work in the people most likely to try it is what is needed next.

Small trials and surveyseLife, 2021 →Translational Psychiatry, 2022 →Harm Reduction Journal, 2019 →

An open question: whole mushrooms versus isolated psilocybin

Most of the clinical trials above, on depression, smoking, and headache, used psilocybin on its own, made in a lab. A mushroom is not that. It holds psilocybin alongside several close relatives and a great deal of other natural material. The two microdosing studies did use whole dried mushrooms, but they compared them with a placebo, not with isolated psilocybin. We have not found a human trial that compares the whole mushroom with the isolated version directly.

There is one early hint. In a 2024 study in mice, an extract of the whole mushroom changed proteins involved in connection between brain cells more, and for longer, than pure psilocybin given at the same amount. The immediate effects looked similar.

Not yet studied

That was a mouse study with no behavioral testing, and it tells us nothing yet about people. Whether the whole mushroom behaves differently from isolated psilocybin in humans is an open question. We are curious about it, and we will update this page as real evidence arrives.

Molecular Psychiatry, 2024 →

Community experiences

Personal accounts, not evidence

Alongside the research there are a great many personal accounts. People describe feeling calmer, more focused, more creative, or more connected to the people and places around them. Others describe discomfort or a hard stretch they did not expect.

These stories matter because they point researchers toward questions worth testing. They are not controlled results, and they cannot tell us what caused what. Everyone's experience is different.

Survey of 278 microdosers, 2019 →

Cautions worth taking seriously

Everyone in the studies above was screened by clinicians and supported through the experience. That is very different from trying something on your own, and it is part of why the results look the way they do.

  • Psychosis or bipolar disorder. A personal or family history is a standard reason to be excluded from trials, and a reason to talk with a doctor first.
  • Pregnancy and nursing. There is not enough safety research to say anything reassuring.
  • Heart conditions and blood pressure. Trials report temporary rises in blood pressure and heart rate.
  • Medications. Antidepressants (SSRIs and SNRIs), St. John's wort, antipsychotics, and benzodiazepines can change how these mushrooms affect you or add risk. Never stop a prescription on your own. Talk to your doctor or pharmacist.

If you ever do explore this, the common advice in the research community is to start low, go slowly, and not do it alone the first time.

This page is for adults 21 and older. It summarizes published research for education only. It is not medical or legal advice, and it makes no claim that any product sold by Luna treats, cures, prevents, or helps any condition. Laws about these mushrooms vary by place, and you are responsible for knowing yours.

Research moves quickly. We last checked this page against its sources on , and we will correct it if we get something wrong.